Compare Global X Autonomous & Electric Vehicles (DRIV) vs Inovio Pharmaceuticals Inc (INO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Global X Autonomous & Electric Vehicles vs Inovio Pharmaceuticals Inc — how do they compare? Global X Autonomous & Electric Vehicles trades at $32.76 (market cap $356.37M), while Inovio Pharmaceuticals Inc trades at $1.15 (market cap $112.19M). The key difference: Global X Autonomous & Electric Vehicles is far larger — about 3.2× Inovio Pharmaceuticals Inc's market cap, and Global X Autonomous & Electric Vehicles is trading nearer its 52-week high, Inovio Pharmaceuticals Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Global X Autonomous & Electric Vehicles for 40 Days and Inovio Pharmaceuticals Inc for 43 Days on average.
| DRIV | INO | |
|---|---|---|
Market Cap | $356.37M | $112.19M |
Volume | 22,397 | 3,201,278 |
Sector | Sector/Thematic | Health |
52-Week High | $42.53 | $2.65 |
52-Week Low | $27.58 | $0.66 |
Typical Hold Time | 40 Days | 43 Days |
Enterprise Value | — | $83.51M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
DRIV trades at $33.37, down 1.68% today amid mixed technical signals. The overall technical outlook is bullish with neutral oscillators, while key support sits at $33. Recent news highlights automotive sector focus on hybrid and electric vehicles, though company-specific financial ratios are currently unavailable for analysis.
The stock shows technical resilience near support levels with bullish momentum indicators. Investment appeal hinges on forthcoming financial disclosures and sector trends favoring EV/hybrid adoption. Key risks include sector competition and reliance on broader automotive market performance without current fundamental data.
INO trades at $1.15, down 0.43% on the day, with a bearish technical signal from moving averages and oscillators. The company shows consistent quarterly earnings beats but operates at significant losses with a -130,000% net income margin and negative cash flow. Key catalyst is the FDA's October 30, 2026 PDUFA date for INO-3107, with analyst consensus leaning bullish at a $2.75 price target.
The investment case hinges on FDA approval of INO-3107, offering substantial upside from current levels. However, persistent cash burn, minimal revenue, and high valuation multiples relative to sales pose significant risks. Investors face binary outcomes driven by regulatory decisions and commercialization execution.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Global X Autonomous & Electric Vehicles
DRIV invests in companies involved in autonomous driving and electric vehicle production. It tracks the Solactive Autonomous & Electric Vehicles Index, focusing on software and hardware leaders like Tesla, NVIDIA, and Microsoft.
Read more on DRIV →About Inovio Pharmaceuticals Inc
Inovio Pharmaceuticals Inc is a United States based biotechnology company that develops active DNA-based immunotherapies and vaccines to treat and prevent cancers and infectious diseases. The company is engaged in gene therapy, where its immunotherapy platform consists of DNA-based immunotherapy and electroporation delivery technologies.
Read more on INO →
